gemcitabine has been researched along with hyaluronoglucosaminidase in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Cappellacci, L; Franchetti, P; Graser, G; Grifantini, M; Jayaram, HN; Lavecchia, A; Petrelli, R; Saiko, P; Szekeres, T; Vita, P | 1 |
| Chang, AE; Cuevas, C; Goel, VK; Hingorani, SR; Provenzano, PP; Von Hoff, DD | 1 |
| Bapiro, TE; Caldwell, ME; Chan, DS; Cook, N; Feig, C; Frese, KK; Frost, GI; Jacobetz, MA; Jiang, P; Jodrell, DI; Kultti, A; Lolkema, MP; Maneval, DC; Nakagawa, T; Neesse, A; Shepard, HM; Skepper, JN; Thompson, CB; Tuveson, DA; Zecchini, HI | 1 |
| Gress, TM; Michl, P | 1 |
| Saif, MW; Strimpakos, AS | 1 |
| Beck, JT; Berdov, BA; Devoe, CE; Dychter, S; Gladkov, OA; Harris, WP; Hingorani, SR; Holcombe, RF; Jiang, P; Korn, R; Pshevlotsky, EM; Raghunand, N; Shepard, HM; Tjulandin, SA; Wagner, SA | 1 |
| Aldrich, C; Bahary, N; Braiteh, F; Bullock, AJ; Chondros, D; Harris, WP; Hendifar, AE; Hingorani, SR; Jiang, P; Khelifa, S; Oberstein, PE; Pu, J; Ritch, PS; Seery, TE; Sigal, DS; Wang-Gillam, A; Wu, W; Zalupski, MM; Zheng, L | 1 |
| Corrie, PG; Doherty, GJ; Tempero, M | 1 |
| Gourd, E | 1 |
| Bekaii-Saab, T | 1 |
| Chen, J; Vermolen, FJ; Weihs, D | 1 |
| Azih, I; Escudero, DO; Ghosh, S; Hasanali, SL; Hennig, M; Hupe, MC; Jordan, AR; Kuczyk, MA; Lokeshwar, VB; Lopez, LE; Merseburger, AS; Morera, DS; Racine, RR; Sarcan, S; Terris, MK; Wang, J; Zhou, M; Zhu, H | 1 |
4 trial(s) available for gemcitabine and hyaluronoglucosaminidase
| Article | Year |
|---|---|
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dexamethasone; Disease-Free Survival; Female; Gemcitabine; Humans; Hyaluronoglucosaminidase; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Russia; Treatment Outcome; United States | 2016 |
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Enoxaparin; Female; Fibrinolytic Agents; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Thromboembolism; Time Factors | 2018 |
HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2018 |
PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Hyaluronoglucosaminidase; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; San Francisco; Survival Rate; Treatment Outcome | 2018 |
9 other study(ies) available for gemcitabine and hyaluronoglucosaminidase
| Article | Year |
|---|---|
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
Topics: Adenosine; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Humans; Ribonucleotide Reductases; Ribose; Structure-Activity Relationship | 2008 |
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Deoxycytidine; Drug Evaluation, Preclinical; Extracellular Fluid; Gemcitabine; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Microvessels; Pancreatic Neoplasms; Polyethylene Glycols; Stromal Cells; Tumor Microenvironment | 2012 |
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Hyaluronic Acid; Hyaluronoglucosaminidase; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Mice, Transgenic; Pancreatic Neoplasms; Recombinant Proteins; Tissue Array Analysis; Treatment Outcome | 2013 |
Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Adhesion Molecules; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Pancreatic Neoplasms; Recombinant Proteins | 2012 |
Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Furans; Gemcitabine; Humans; Hyaluronoglucosaminidase; Lignans; Mutation; Pancreatic Neoplasms; Polyethylene Glycols; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Recombinant Proteins; RNA Interference; Treatment Outcome | 2013 |
PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Paclitaxel; Pancreatic Neoplasms | 2018 |
New guideline-sanctioned and emerging interventions for pancreatic cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Histone Acetyltransferases; Humans; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Pancreas; Pancreatic Neoplasms | 2018 |
Computational modeling of therapy on pancreatic cancer in its early stages.
Topics: Anisotropy; Cell Death; Cell Division; Cell Line, Tumor; Cell Movement; Computer Simulation; Deoxycytidine; Extracellular Matrix; Gemcitabine; Humans; Hyaluronoglucosaminidase; Injections; Monte Carlo Method; Neoplasm Staging; Numerical Analysis, Computer-Assisted; Pancreatic Neoplasms; Stochastic Processes | 2020 |
HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Chondroitinases and Chondroitin Lyases; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Histone Acetyltransferases; Humans; Hyaluronoglucosaminidase; Mice; Prognosis; Treatment Failure; Urinary Bladder Neoplasms | 2021 |